Tip of the iceberg: Investigating in hart to treat indications like Glioblastoma and Pancreatic cancer, TME Pharma is hoping for proof of therapeutic superiority and many more indications to adress (©TME Pharma NV)

TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.

Mark Kotter, Cambridge, Picture:  © Bit.bio

At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.

Picture: 2024 Mack-Brooks Exhibitions - Part of RX, St Albans, UK

Connect with the world of fine and speciality chemicals: taking place from 19-20 June 2024 at the Messe Düsseldorf exhibition centre in Germany, Chemspec Europe is the key marketplace to showcase the full array of fine and speciality chemicals, bespoke ­solutions, services, and equipment.  

Double invest by Forbion in quite different topics: in-vivo celltherapy and neurological disorders. (courtesey Capstan Inc.; Engrail Thx)

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.

Richter-Helm´s expanded manufacturing site at Bovenau, Germany  ready to manufacture your product; ©Richter-Helm

Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly increased its manufacturing capacities for biopharmaceutical products at its production site in Bovenau, Germany.

At the end of February, 200 German clinical trial experts gathered in Frankfurt/Main to discuss with representatives of the German Ministry of Health, how to implement model contract clauses into a law that speeds up clinical trials and translational medicine in Germany. According Model contract clauses have been established before by stakeholders from Deutsche Hochschulmedizin, das KKS-Netzwerk, die Pharmaverbände vfa und BPI sowie der CRO-Verband BVMA. © BVMA

With a new law, the German government wants to increase the number of clinical trials conducted in Germany and make the country number one in Europe again.

IgA depostis (green) in glomeruli of humanised mice. © Patrick Gleeson, University College Cork

A bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system.

Myo-satellite cells grown in Innocent Meat's serum-free growth medium. © Innocent Meat

Cultivated meat producer Innocent Meat GmbH has cashed in €3m in funding from Venture Capital Fonds MV and an anonymous business angel.

Group Ferrer is headquartered in Barcelona, Catalonia, Spain. © Ferrer

Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.

Ion Arocena; General Manager Asebio; © Asebio

Born with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information System CTIS, particularly with regard to SMEs and translational researchers.